Abstract
Simple Summary: Genetically heterogeneous disorder acute myeloid leukemia (AML) is marked by recurring mutations in FLT3. Current FLT3 inhibitors and ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
